analgesic after total hip arthroplasty.
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Body Mass Index (BMI): 18-26 kg/m^2 (inclusive of boundary values); 2.Patients scheduled for total hip arthroplasty. 3.ASA classification of 1-3. 4.Voluntary participation in this study with a signed informed consent form. If the participant is unable to read or sign the informed consent form due to incapacity, their legal guardian must oversee the informed consent process and sign the form on their behalf. For participants unable to read the informed consent form (e.g., illiterate individuals), a witness must be present during the informed consent process and sign the form as a witness; 5.18-80 years old (including boundary values).
Exclusion criteria
Exclusion criteria: 1.Severe diseases of major organs and systems; 2.Inability to tolerate general anesthesia; 3.Chronic pain conditions; 4.Coagulation disorders; 5.Infection at the injection site; 6.Peripheral nervous system disorders; 7.Inability to communicate or cooperate; 8.History of allergy to local anesthetics; 9.Contraindications to any of the drugs used in the study protocol; 10.Vulnerable populations other than the elderly or illiterate individuals, including those with: psychiatric disorders, cognitive impairment, critical illness, pregnancy, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Consumption of sufentanil; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hip joint range of motion;Maximum NRS (Numerical Rating Scale) score;Time to first rescue analgesia;Consumption of sufentanil;The QoR-15 Quality of Recovery Scale;Postoperative adverse events;Quadriceps Manual Muscle Testing;Measuring the area of skin sensory block with cold stimulation;First time walking; | — |
Countries
China
Contacts
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University